ReviewMolecules (Basel, Switzerland)2025
Structural Aspects of Arylpiperazines as Aminergic GPCR Ligands.
Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Arylpiperazines are considered a "privileged scaffold" in medical chemistry due to their versatility and modular structure, enabling modifications towards diverse molecular targets with desired potency, selectivity, and pharmacokinetic properties. In particular, arylpiperazines are aminergic G protein-coupled receptor (GPCR) ligands and neurotransmitter transporter inhibitors, making this group of compounds attractive in central nervous system (CNS) drug discovery for treating schizophrenia, depression, sleep disorders, and Parkinson's disease (PD). Furthermore, arylpiperazines may possess anticancer properties and can modulate some molecular targets involved in this disease. This review focuses on the structural aspects of arylpiperazines as aminergic GPCR ligands. The review centers on biologically active arylpiperazines with known X-ray structures, providing a detailed discussion of the conformations in the solid state. Next, their interactions with the aminergic GPCRs, based on experimental and molecular modelling studies, are addressed, making this review a comprehensive resource for medicinal and structural chemists working on arylpiperazines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.